|
Idenix Confident in Safety Advantage of Hep C Drug Despite Trial Hold
Idenix remains confident that its lead product candidate, hepatitis C drug IDX184, has a safety advantage over a similar Bristol-Myers Squibb (BMS) competitor despite a partial clinical hold placed on IDX184 following adverse heart events seen in BMS’ trials.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives